David Call
Internal Medicine · Millport, ALNPI 1245233667
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,423 and has fallen 96.1% since, to $56 in 2024.
Across 316 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$676
- Johnson & Johnson$515
- AbbVie$438
- Lilly USA, LLC$343
- Novartis$250
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$250
- plus $2K from 37 others
What the payments were for
- Food & beverage$4,67698%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,776 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 44 | $49,084 |
| FarxigaDapagliflozin Propanediol | 42 | $40,056 |
| OzempicSemaglutide | 17 | $25,440 |
| XareltoRivaroxaban | 16 | $16,534 |
| EliquisApixaban | 20 | $12,639 |
| VraylarCariprazine Hcl | 11 | $7,884 |
| CreonLipase/Protease/Amylase | 16 | $6,522 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $5,421 |
| Esomeprazole Magnesium | 13 | $2,553 |
| Pantoprazole Sodium | 79 | $2,378 |
| Atorvastatin Calcium | 129 | $2,365 |
| Memantine Hcl ErMemantine Hcl | 11 | $1,209 |
| Memantine Hcl | 13 | $1,012 |
| Omeprazole | 56 | $914 |
| Simvastatin | 41 | $907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $76 | $49,08444 claims |
| AstraZenecaFarxiga, Symbicort | $121 | $45,47753 claims |
| Novo NordiskOzempic | $676 | $25,44017 claims |
| Johnson & JohnsonXarelto | $515 | $16,53416 claims |
| AbbVieVraylar, Creon | $438 | $14,40627 claims |
| PfizerEliquis | $210 | $12,63920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Millport
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
- Thomas HuddleBirmingham$76K
- Rahel AzizMobile$67K
- Justin HoveyDothan$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.